IGM Biosciences Inc (IGMS)
10.12
-1.10
(-9.76%)
USD |
NASDAQ |
Nov 14, 16:00
11.07
+0.94
(+9.33%)
After-Hours: 18:31
IGM Biosciences Enterprise Value: 409.17M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 409.17M |
| November 12, 2024 | 416.89M |
| November 11, 2024 | 507.64M |
| November 08, 2024 | 516.54M |
| November 07, 2024 | 596.03M |
| November 06, 2024 | 608.49M |
| November 05, 2024 | 682.63M |
| November 04, 2024 | 674.33M |
| November 01, 2024 | 705.77M |
| October 31, 2024 | 760.34M |
| October 30, 2024 | 787.63M |
| October 29, 2024 | 767.46M |
| October 28, 2024 | 801.27M |
| October 25, 2024 | 742.55M |
| October 24, 2024 | 683.23M |
| October 23, 2024 | 694.50M |
| October 22, 2024 | 778.73M |
| October 21, 2024 | 673.14M |
| October 18, 2024 | 735.43M |
| October 17, 2024 | 694.50M |
| October 16, 2024 | 584.16M |
| October 15, 2024 | 658.91M |
| October 14, 2024 | 740.17M |
| October 11, 2024 | 633.40M |
| October 10, 2024 | 567.56M |
| Date | Value |
|---|---|
| October 09, 2024 | 549.76M |
| October 08, 2024 | 606.71M |
| October 07, 2024 | 557.47M |
| October 04, 2024 | 657.72M |
| October 03, 2024 | 627.47M |
| October 02, 2024 | 597.81M |
| October 01, 2024 | 603.74M |
| September 30, 2024 | 724.75M |
| September 27, 2024 | 752.04M |
| September 26, 2024 | 684.41M |
| September 25, 2024 | 717.04M |
| September 24, 2024 | 745.51M |
| September 23, 2024 | 692.12M |
| September 20, 2024 | 702.21M |
| September 19, 2024 | 765.68M |
| September 18, 2024 | 731.28M |
| September 17, 2024 | 792.37M |
| September 16, 2024 | 683.23M |
| September 13, 2024 | 473.24M |
| September 12, 2024 | 419.26M |
| September 11, 2024 | 440.02M |
| September 10, 2024 | 412.14M |
| September 09, 2024 | 352.82M |
| September 06, 2024 | 295.88M |
| September 05, 2024 | 351.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-156.95M
Minimum
Oct 31 2023
3.510B
Maximum
Feb 09 2021
919.41M
Average
556.75M
Median
May 06 2022
Enterprise Value Benchmarks
| Moderna Inc | 9.349B |
| NovaBay Pharmaceuticals Inc | 3.432M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 6.814M |
| Theriva Biologics Inc | -13.26M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -47.90M |
| Revenue (Quarterly) | 1.254M |
| Total Expenses (Quarterly) | 52.61M |
| EPS Diluted (Quarterly) | -0.79 |
| Profit Margin (Quarterly) | -3.82K% |
| Earnings Yield | -35.95% |
| Normalized Earnings Yield | -35.95 |